Literature DB >> 2814170

Clinical pathologic correlations of Lyme disease.

P H Duray1.   

Abstract

The multisystem effects caused by Borrelia burgdorferi in Lyme disease are multiple, varied, and unpredictable. In some patients, the full extent of the infection consists of a stage I acute systemic viral-like illness. Stage II primarily involves the cardiovascular system (myocarditis) and/or the central nervous system (CNS) (meningoencephalitis, polyradiculitis). More inflammatory cells are found in the heart and nervous system structures during this intermediate stage than are found in any tissues involved during stage I. Stage III is characterized by peripheral neuropathy and CNS disorders such as dementia or transverse myelitis and arthritis and synovitis of large joints such as the knee. Chronic Lyme disease is also associated with multiple and seemingly unrelated cutaneous manifestations such as acrodermatitis chronica atrophicans, sclerodermoid-like reactions, lichen sclerosus et atrophicus, subcuticular fibrous nodules, eosinophilic fasciitis-like lesions of the extremities, and, possibly, granuloma annulare. With care, spirochetes can be recovered or demonstrated by silver staining in most of the above lesions. Spirochetes have yet to be seen in the tissues of autonomic ganglia or peripheral nerves.

Entities:  

Mesh:

Year:  1989        PMID: 2814170     DOI: 10.1093/clinids/11.supplement_6.s1487

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  18 in total

1.  Orbital Lyme disease: MR imaging before and after treatment: case report.

Authors:  Girish M Fatterpekar; Robin I Gottesman; Michael Sacher; Peter M Som
Journal:  AJNR Am J Neuroradiol       Date:  2002-04       Impact factor: 3.825

2.  Expression of ICAM-1, ICAM-2, NCAM-1 and VCAM-1 by human synovial cells exposed to Borrelia burgdorferi in vitro.

Authors:  Sunit K Singh; Verena Baar; Henner Morbach; Hermann J Girschick
Journal:  Rheumatol Int       Date:  2005-11-24       Impact factor: 2.631

Review 3.  Laboratory diagnosis of Lyme disease: advances and challenges.

Authors:  Adriana R Marques
Journal:  Infect Dis Clin North Am       Date:  2015-06       Impact factor: 5.982

Review 4.  Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.

Authors:  Daniel J Cameron; Lorraine B Johnson; Elizabeth L Maloney
Journal:  Expert Rev Anti Infect Ther       Date:  2014-07-30       Impact factor: 5.091

5.  Comparison of protection in rabbits against host-adapted and cultivated Borrelia burgdorferi following infection-derived immunity or immunization with outer membrane vesicles or outer surface protein A.

Authors:  E S Shang; C I Champion; X Y Wu; J T Skare; D R Blanco; J N Miller; M A Lovett
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

6.  Biased T-cell antigen receptor repertoire in Lyme arthritis.

Authors:  K Roessner; H Trivedi; L Gaur; D Howard; J Aversa; S M Cooper; L H Sigal; R C Budd
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

Review 7.  Childhood Lyme borreliosis in Europe.

Authors:  H I Huppertz
Journal:  Eur J Pediatr       Date:  1990-09       Impact factor: 3.183

Review 8.  Physician preferences in the diagnosis and treatment of Lyme disease in the United States.

Authors:  M H Ziska; S T Donta; F C Demarest
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

9.  Diagnostic value of PCR for detection of Borrelia burgdorferi in skin biopsy and urine samples from patients with skin borreliosis.

Authors:  S Brettschneider; H Bruckbauer; N Klugbauer; H Hofmann
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

10.  Dermal inflammation elicited by synthetic analogs of Treponema pallidum and Borrelia burgdorferi lipoproteins.

Authors:  M V Norgard; B S Riley; J A Richardson; J D Radolf
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.